Following screening, subjects meeting all eligibility criteria will undergo leukapheresis to obtain cells for the manufacture of autologous AFP TCR bearing T cells. All eligibility criteria will be reconfirmed and baseline tumor measurements will be obtained prior to lymphodepleting therapy.